Brahm Goldstein

Brahm Goldstein, MD, MCR has been the Vice President, Research and Development, Hematology at CSL Behring since 2020. During his time at CSL, Brahm has expanded the hematology therapeutic area both in terms of building a strong multifunctional team and achieving accomplishments including: successful completion of the global Phase 3 studies for Afstyla and Idelvion; start of the Phase 1 study for CSL889 (hemopexin for treatment of sickle cell disease); development of CSL888 (haptoglobin for treatment of subarachnoid hemorrhage); and, as of 22 November 2022, BLA approval from the FDA for Hemgenix, the first gene therapy approved for selected patients with hemophilia B.

Brahm has an MD degree from SUNY Health Science Center and a Masters in Clinical Research from Oregon Health & Science University. He has held leadership roles in the biotechnology and pharmaceutical industry for the past 16 years at several companies including Novo Nordisk, Ikaria, Baxter, Shire, and Global Blood Therapeutics. Prior to transitioning to the pharmaceutical industry, Brahm was in academic medicine for over 25 years as a pediatric critical care physician with positions at Massachusetts General Hospital/Harvard Medical School, University of Rochester School of Medicine and Dentistry, and Oregon Health & Sciences University. He received multiple scientific research grant awards and has authored over 250 peer-reviewed manuscripts, abstracts, reviews, and books.